Parse Biosciences to Participate in Canaccord Genuity Investor Conference
CEO and co-founder Alex Rosenberg, Ph.D. joining panel discussion at November 17 event in New York
Senior executives from Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, will participate in the Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum. The one-day event will profile public and private companies across the medical technology, diagnostic and digital health & services sectors.
Parse Biosciences CEO and co-founder Alex Rosenberg, Ph.D. will participate on a panel titled, “Oh Me, Oh My, Multiomics: A Panel Discussion of Scientists and Executives Highlighting Spatial Biology, Single Cell Analysis, Proteomics and Morpholomics.”
Alex Rosenberg and Parse Biosciences CFO Britton Russell will be available for one-on-one meetings with institutional investors during the conference.
Panel: Thursday, November 17, 1:00 – 1:55 pm
The Westin New York Grand Central
212 E 42nd St, New York, NY 10017
Investors: Robert Uhl, ICR Westwicke: email@example.com | 619.228.5886
Media: Lisa Owen, Parse Biosciences: firstname.lastname@example.org | 206-851-6246
About Parse Biosciences
Parse Biosciences is a leading provider of accessible and scalable single cell sequencing solutions with the mission of accelerating progress in human health and scientific research. The company’s pioneering approach for single cell sequencing has already enabled groundbreaking discoveries which have led to new understandings of cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. The company’s commercially available instrument-free products provide researchers with the ability to perform single cell sequencing at low cost with unprecedented scale and ease. Parse Biosciences is headquartered in Seattle.